These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 11366804)
41. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA. WHO/UNAIDS/IAVI International Expert Group AIDS; 2007 Feb; 21(4):539-46. PubMed ID: 17301582 [TBL] [Abstract][Full Text] [Related]
42. HIV vaccine update: recent developments and current trials. Lally M; Lemei K; Mayer K Med Health R I; 2007 Oct; 90(10):318-20. PubMed ID: 18019189 [No Abstract] [Full Text] [Related]
43. Rebuilding the immune system: promising new therapy uses the HIV virus itself to awaken the damaged immune system. Interview by Brian Coppedge and Dan Dawson. Moss R STEP Perspect; 1998; 98(2):13-6. PubMed ID: 11365540 [TBL] [Abstract][Full Text] [Related]
44. An HIV vaccine: as we build it, will they come? McCluskey MM; Alexander SB; Larkin BD; Murguia M; Wakefield S Health Aff (Millwood); 2005; 24(3):643-51. PubMed ID: 15886155 [TBL] [Abstract][Full Text] [Related]
45. HIV vaccine study approved. Expert Rev Vaccines; 2010 Jul; 9(7):693. PubMed ID: 20624040 [No Abstract] [Full Text] [Related]
46. An AIDS vaccine for all the world. Interview by Matthew O'Rourke. Berkley S AIDS Clin Care; 1999 Jul; 11(7):55-7, 62. PubMed ID: 11366434 [TBL] [Abstract][Full Text] [Related]
47. Preparedness for AIDS vaccine trials in India. Excler JL; Kochhar S; Kapoor S; Das S; Bahri J; Ghosh MD; Ganguly NK; Nayyar A; Chataway M Indian J Med Res; 2008 Jun; 127(6):531-8. PubMed ID: 18765870 [TBL] [Abstract][Full Text] [Related]
48. Clinton sets goal of having an AIDS vaccine in 10 years. AIDS Policy Law; 1997 Jun; 12(11):3. PubMed ID: 11364387 [TBL] [Abstract][Full Text] [Related]
49. AIDS vaccine research and advocacy: an update. Bass E; Feuer C; Warren M BETA; 2009; 21(2):24-30. PubMed ID: 19517626 [No Abstract] [Full Text] [Related]
50. HIV vaccines need to be developed: interview with Sam Avrett, International AIDS Vaccine Initiative. Interview by John S. James. Avrett S AIDS Treat News; 1997 May; (No 270):4-6. PubMed ID: 11364325 [TBL] [Abstract][Full Text] [Related]
51. HIV-1 vaccine clinical trials: the Brazilian experience. Ersching J; Pinto AR Rev Med Virol; 2009 Sep; 19(5):301-11. PubMed ID: 19650156 [TBL] [Abstract][Full Text] [Related]
52. The challenges of HIV vaccine development and testing. Burgers WA; Williamson C Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):277-91. PubMed ID: 15778116 [TBL] [Abstract][Full Text] [Related]
53. Human versus HIV: round 2 defeat in AIDS vaccine development. Lu S Expert Rev Vaccines; 2008 Mar; 7(2):151-3. PubMed ID: 18324884 [No Abstract] [Full Text] [Related]
54. How should HIV vaccine efficacy trials be conducted? Diverse U.S. communities speak out. Kegeles SM; Johnson MO; Strauss RP; Ralston B; Hays RB; Metzger DS; McLellan-Lemal E; MacQueen KM AIDS Educ Prev; 2006 Dec; 18(6):560-72. PubMed ID: 17166081 [TBL] [Abstract][Full Text] [Related]
55. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576 [No Abstract] [Full Text] [Related]
56. Agouron and immune response to commercialize remune immune-based treatment. James JS AIDS Treat News; 1998 Jun; (No 297):1. PubMed ID: 11365593 [TBL] [Abstract][Full Text] [Related]